Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALPG | P10696 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylamine SCHEMBL6615357 | 0.95 | MAPT (0.59) | MAPTPKMLMNAL3MBTL1MAPK1 | |
| SCHEMBL5149985 | 0.87 | ALDH1A1 (0.67) | MAPTPKMLMNAL3MBTL1MAPK1 | |
| SCHEMBL11048929 | 0.84 | MAPT (0.65) | MAPTPKMLMNAL3MBTL1MAPK1 | |
| SCHEMBL23144863 | 0.83 | MAPT (0.59) | MAPTPKMLMNAL3MBTL1MAPK1 | |
| SCHEMBL989963 | 0.83 | MAPT (0.60) | MAPTPKMLMNAL3MBTL1MAPK1 | |
| SCHEMBL7767318 | 0.82 | MAPT (0.62) | MAPTPKMLMNAL3MBTL1MAPK1 | |
| SCHEMBL10881383 | 0.82 | TDP1 (0.61) | MAPTPKMLMNAL3MBTL1MAPK1 | |
| SCHEMBL981242 | 0.81 | KAT2B (0.64) | MAPTLMNAL3MBTL1MAPK1ALDH1A1 | |
| SCHEMBL17749591 | 0.81 | MAPT (0.61) | MAPTPKMLMNAL3MBTL1MAPK1 | |
| SCHEMBL5309199 | 0.81 | MAPT (0.66) | MAPTPKMLMNAL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079087-A1 | ENAC BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1368342-B1 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050153978-A1 | Medicaments | GLAXO GROUP LIMITED (GB) | 2005-07-14 | — | — | US | disclosed |
| CN-1553909-A | Benzimidazole and pyridylimidazole derivatives as ligands for GABA receptors | — | 2004-12-08 | — | — | CN | disclosed |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-5587392-A | THERAPY FOR ESTROGEN DEPENDENT DISEASES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5534521-A | SEROTONIN ANTAGONISTS | G. D. SEARLE & CO. (US) | 1996-07-09 | — | — | US | disclosed |
| US-5521193-A | SEROTONIN AGONISTS AND ANTAGONISTS | G. D. SEARLE & CO. (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0684235-A1 | Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
| US-5300512-A | Antiserotonine agents; antagonist or agonist | G. D. SEARLE & CO. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5280028-A | Containing ketone structure in position2 | G. D. SEARLE & CO. (US) | 1994-01-18 | — | — | US | disclosed |
| WO-1994000449-A1 | BENZIMIDAZOLE COMPOUNDS | G.D. SEARLE & CO. (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000454-A1 | BENZIMIDAZOLE COMPOUNDS | G.D. SEARLE & CO. (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | MAPT 1046/4885PKM 307/4885LMNA 2796/4885 |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | MAPT 1046/4885PKM 307/4885LMNA 2796/4885 |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | MAPT 1046/4885PKM 307/4885LMNA 2796/4885 |
| US-20050153978-A1 | Medicaments | GRK1, ROCK1, GRK7 | MAPT 3107/4885PKM 1825/4885LMNA 3812/4885 |
| US-20030069257-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABRA1, GABBR2 | MAPT 977/4885PKM 277/4885LMNA 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.